Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder, major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), today announced that CEO Stephan Jackman will be interviewed on the Fox Business Network news channel on Wednesday, November 16, 2022.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, November 15, 2022
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Clinical Trials, PTSD, Clinical research associate, MDD, Risk, Food, Proline, Major depressive disorder, Nature, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Post-traumatic stress disorder, University, Bipolar disorder, Lithium, Pharmaceutical industry
Geotags: 
GEORGIA, UNITED STATES, NORTH AMERICA
⚠ partially generated by AI ↴
Organisation: 
ALZAMEND NEURO, ALZAMEND NEURO, INC.
Stock Symbol: 
NASDAQ:ALZN
Summary
Key Points: 
  • Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder, major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), today announced that CEO Stephan Jackman will be interviewed on the Fox Business Network news channel on Wednesday, November 16, 2022.
  • Mr. Jackman will appear on the Making Money with Charles Payne show that airs between 2 p.m. and 3 p.m.
  • 2023 is shaping up to be an exciting year as we move forward with both clinical programs.
  • Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers, bipolar disorder, MDD and PTSD.


Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that CEO Stephan Jackman will be interviewed on the Fox Business Network news channel on Wednesday, November 16, 2022.

Mr. Jackman will appear on the “Making Money with Charles Payne” show that airs between 2 p.m. and 3 p.m. ET. “I am delighted to discuss the achievements of this past year, including the initiation of a Phase IIA study for AL001, a pre-investigational new drug submission and response for additional indications for AL001, and most recently the favorable response from the U.S. Food and Drug Administration to initiate a Phase I/IIA trial with ALZN002, our immunotherapeutic vaccine,” said Stephan Jackman, Chief Executive Officer of Alzamend. “2023 is shaping up to be an exciting year as we move forward with both clinical programs.”

About Alzamend Neuro

Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, bipolar disorder, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend’s business and financial results are included in Alzamend’s filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend’s website at www.Alzamend.com.

Copyright: 
Copyright Business Wire 2022